On the basis of these findings, the National Comprehensive Cancer Network colorectal cancer guidelines were updated recently to include pertuzumab plus trastuzumab and trastuzumab plus lapatinib as category 2B recommendations for HER2-positive colorectal cancer.47 The gene discussed is ERBB2; the disease is colorectal cancer.